Thoroughbred Financial Services LLC Buys 428 Shares of GSK plc (NYSE:GSK)

Thoroughbred Financial Services LLC raised its stake in GSK plc (NYSE:GSK) by 6.6% in the second quarter, Holdings Channel.com reports. The firm owned 6,908 shares of the pharmaceutical company’s stock after acquiring an additional 428 shares during the period. Thoroughbred Financial Services LLC’s holdings in GSK were worth $265,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. JTC Employer Solutions Trustee Ltd increased its stake in GSK by 71.3% during the first quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock valued at $909,063,000 after acquiring an additional 8,800,822 shares during the period. Hsbc Holdings PLC bought a new stake in shares of GSK during the fourth quarter valued at approximately $92,281,000. Armistice Capital LLC lifted its position in GSK by 670.5% in the fourth quarter. Armistice Capital LLC now owns 2,196,000 shares of the pharmaceutical company’s stock worth $81,384,000 after purchasing an additional 1,911,000 shares during the period. Mondrian Investment Partners LTD boosted its stake in GSK by 37.8% during the first quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock worth $236,250,000 after buying an additional 1,512,442 shares in the last quarter. Finally, Fisher Asset Management LLC increased its holdings in GSK by 10.6% in the 4th quarter. Fisher Asset Management LLC now owns 15,036,881 shares of the pharmaceutical company’s stock valued at $557,267,000 after buying an additional 1,436,488 shares during the period. Institutional investors own 15.74% of the company’s stock.

GSK Trading Down 2.3 %

Shares of GSK opened at $42.55 on Wednesday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The company has a market cap of $88.18 billion, a price-to-earnings ratio of 15.42, a PEG ratio of 1.41 and a beta of 0.66. The stock has a fifty day moving average price of $41.22 and a two-hundred day moving average price of $41.70. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The business had revenue of $9.95 billion during the quarter, compared to analysts’ expectations of $9.49 billion. Analysts predict that GSK plc will post 4.15 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be paid a dividend of $0.3843 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a dividend yield of 3.61%. The ex-dividend date of this dividend is Friday, August 16th. GSK’s dividend payout ratio is 54.71%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Jefferies Financial Group raised their target price on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Citigroup upgraded GSK to a “strong-buy” rating in a research report on Monday, June 24th. Finally, Barclays raised GSK to a “hold” rating in a report on Tuesday, August 27th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.